The role of genistein and melatonin in the correction of vasomotor symptoms, sleep disorders and the prevention of osteoporosis during perimenopause

1. Радзинский В.Е., Ордиянц И.М. Лечение климактерических расстройств в менопаузе. РМЖ. 2018; 5-1(26): 37-40. [Radzinsky V.E., Ordiyants I.M. Treatment of menopausal disorders in menopause. BC. 2018; 5-1(26): 37-40.(in Russian)]
2. Юренева С.В., Ильина Л.М., Эбзиева З.Х. Менопаузальные вазомоторные симптомы: социальные аспекты, динамика, кардиометаболические риски и возможности гормональной терапии. Акушерство и гинекология. 2019; 1: 26-32. [Yureneva S.V., Ilina L.M., Ebzieva Z.Kh. Menopausal vasomotor symptoms: social aspects, dynamics, metabolic risks and possibilities of hormonal therapy. Obstetrics and Gynecology. 2019; 1: 26-32. (in Russian)]
3. Jehan S., Masters-Isarilov A., Salifu I., Zizi F., Jean-Louis G., Pandi-Perumal S.R. et al. Sleep disorders in postmenopausal women. J. Sleep Disord. Ther. 2015; 4(5). pii: 1000212.
4. Hardeland R. Melatonin in aging and disease-multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012; 3(2): 194-225.
5. Miller S.C., Pandi-Perumal S.R., Esquifino A.I., Cardinali D.P., Maestroni G.J. The role of melatonin in immuno-enhancement: potential application in cancer. Int. J. Exp. Pathol. 2006; 87(2): 81-7.
6. Schmidt C., Peigneux P., Leclercq Y., Sterpenich V., Vandewalle G., Phillips C. et al. Circadian preference modulates the neural substrate of conflict processing across the day. PloS One. 2012; 7(1): e29658.
7. Hardeland R. Melatonin and synthetic melatoninergic agonists in psychiatric and age-associated disorders: successful and unsuccessful approaches. Curr. Pharm. Des. 2016; 22(8): 1086-101.
8. Bortolato B., Berk M., Maes M., McIntyre R.S., Carvalho A.F. Fibromyalgia and bipolar disorder: emerging epidemiological associations and shared pathophysiology. Curr. Mol. Med. 2016; 16(2): 119-36.
9. Gumral N., Naziroglu M., Ongel K., Beydilli E.D., Ozguner F., Sutcu R. et al. Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods. Cell Biochem. Funct. 2009; 27(5): 276-83.
10. Hernández C., Abreu J., Abreu P., Castro A., Jiménez A. Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur. Respir. J. 2007; 30(3): 496-500.
11. Lemmer B., Scholtze J., Schmitt J. Circadian rhythms in blood pressure, heart rate, hormones, and on polysomnographic parameters in severe obstructive sleep apnea syndrome patients: effect of continuous positive airway pressure. Blood Press. Monit. 2016; 21(3): 136-43.
12. Mahdi A.A., Fatima G., Das S.K., Verma N.S. Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome. Indian J. Biochem. Biophys. 2011; 48(2): 82-7.
13. Pernambuco A., Schetino L.P., Viana R.S., Carvalho L.S., d’Ávila Reis D. The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome. Clin. Exp. Rheumatol. 2015; 33 (1, Suppl. 88): S14-9.
14. Eichling P.S., Sahni J. Menopause related sleep disorders. J. Clin. Sleep Med. 2005; 1(3): 291-300.
15. Wurtman R.J. Use of melatonin to promote sleep in older people. Eur. Neurol. Rev. 2012; 8(1): 10-1.
16. Al-Safi Z.A., Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertil. Steril. 2014; 101(4): 905-15.
17. Lassila H., Johns N.P., O’Neil C.K., Johns J.R., Balk J.L., Witt-Enderby P.A. Alternative options to manage menopausal symptoms with a focus on melatonin and osteoporosis. Clin. Pharmacol. Biopharm. 2014; 3: 115.
18. Kotlarczyk M.P., Lassila H.C., O’Neil C.K., D’Amico F., Enderby L.T., Witt-Enderby P.A. et al. Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J. Pineal Res. 2012; 52(4): 414-26.
19. Hardeland R. Melatonin and the theories of aging: a critical appraisal of melatonin’s role in antiaging mechanisms. J. Pineal Res. 2013; 55(4): 325-56.
20. Karasek M. Melatonin, human aging, and age-related diseases. Exp. Gerontol. 2004; 39(11-12): 1723-9.
21. Быков Ю.В., Ханнанова А.Н., Беккер Р.А. Мелатонин и бензодиазепины в лечении инсомнии: за и против (обзор литературы). В мире научных открытий. 2016; 7: 60-82. [Bykov Yu.V., Hannanova A.N., Becker R.A. Melatonin and benzodiazepines in the treatment of insomnia: the pros and cons (literature review). In the World of Scientific Discoveries. 2016. 7 (79): 60-72.(in Russian)]
22. Manber R., Armitage R. Sex, steroids, and sleep: a review. Sleep. 1999; 22(5): 540-55.
23. Prinz P., Bailey S., Moe K., Wilkinson C., Scanlan J. Urinary free cortisol and sleep under baseline and stressed conditions in healthy senior women: effects of estrogen replacement therapy. J. Sleep Res. 2001; 10(1): 19-26.
24. Halbreich U. Role of estrogen in postemenopausal depression. Neurology. 1997; 48(5, Suppl. 7): 16-9.
25. Antonijevic I.A., Stalla G.K., Steiger A. Modulation of sleep electroencephalogram by estrogen replacement in postmenopausal women. Am. J. Obstet. Gynecol. 2000; 182(2): 277-82.
26. Cintron D., Lipford M., Larrea-Mantilla L., Spencer-Bonilla G., Lloyd R., Gionfriddo M.R. et al. Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. Endocrine. 2017; 55(3): 702-11.
27. Cardini F., Lesi G., Lombardo F., van der Sluijs C. MSCG – Menopause Survey Collaborative Group. The use of complementary and alternative medicine by women experiencing menopausal symptoms in Bologna. BMC Womens Health. 2010; 10: 7.
28. Imhof M., Gocan A., Imhof M., Schmidt M. Soy germ extract alleviates menopausal hot fl ushes: placebo-controlled double-blind trial. Eur. J. Clin. Nutr. 2018; 72(7): 961-70.
29. Henderson V.W., St John J.A., Hodis H.N., Kono N., McCleary C.A., Franke A.A., Mack W.J.; WISH Research Group. Long-term soy isofl avone supplementation and cognition in women: A randomized, controlled trial. Neurology. 2012; 78(23): 1841-8.
30. Rondanelli M., Opizzi A., Monteferrario F., Antoniello N., Manni R., Klersy C. The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial. J. Am. Geriatr. Soc. 2011; 59(1): 82-90.
31. Marini H., Minutoli L., Polito F., Bitto A., Altavilla D., Atteritano M. et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann. Intern. Med. 2007; 146(12):839-47.
32. Marini H., Minutoli L., Polito F., Bitto A., Altavilla D., Atteritano M. et al. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration. J. Bone Miner. Res. 2008; 23(5): 715-20.
33. Lutsenko A.S., Rozhinskaya L.Y., Toroptsova N.V., Belaya Z.E. The role of calcium and vitamin D medications in prevention and treatment of osteoporosis. Osteoporos. Bone Dis. 2017; 20(2): 69-75.
34. Saha P., Verma S., Das P.S. Sublingual drug delivery: an indication of potential alternative route. Int. J. Curr. Pharm. Res. 2017; 9(6): 5-7.
35. Лесняк О.М., Никитинская О.А., Торопцова Н.В., Белая Ж.Е., Белова К.Ю., Бордакова Е.В., Гильманов А.Ж., Гуркина Е.Ю., Дорофейков В.В., Ершова О.Б., Зазерская И.Е., Зоткин Е.Г., Каронова Т.Л., Марченкова Л.А., Назарова А.В., Пигарова Е.А., Рожинская Л.Я., Сафонова Ю.А., Скрипникова И.А., Ширинян Л.В. и др. Профилактика, диагностика и лечение дефицита витамина D и кальция у взрослого населения России и пациентов с остеопорозом (по материалам подготовленных клинических рекомендаций). Научно-практическая ревматология. 2015; 53(4): 403-8. [Lesnyak O.M., Nikitinskaya O.A., Toroptsova N.V., et al. The prevention, diagnosis, and treatment of vitamin D and calcium deficiencies in the adult population of Russia and in patients with osteoporosis (according to the materials of prepared clinical recommendation). Nauchno-Prakticheskaya Revmatologiya – Rheumatology Science and Practice. 2015; 53(4): 403-408 (in Russian]. http://dx.doi.org/10.14412/1995-4484-2015-403-408.
36. Добровольская О.В., Сафонова Ю.А., Торопцова Н.В., Зоткин Е.Г. Приверженность терапии комбинированным препаратом кальция и витамина D при разных режимах дозирования. Фарматека. 2011; 10: 75-9. [Dobrovolskaya O.V., Safonova Yu.A., Toroptsova N.V., Zotkin E.G. Adherence to therapy with the combined preparation of calcium and vitamin D with different dosing regimens. Farmateka. 2011; 10: 75-79. (in Russian)]

Received 19.06.2019

Accepted 21.06.2019